Research ArticleArticle
Systemic Sclerosis in Canada's North American Native Population: Assessment of Clinical and Serological Manifestations
Adrienne Bacher, Shikha Mittoo, Marie Hudson, Solène Tatibouet, the Canadian Scleroderma Research Group and Murray Baron
The Journal of Rheumatology May 2013, jrheum.121212; DOI: https://doi.org/10.3899/jrheum.121212
Adrienne Bacher
From the Department of Internal Medicine, University of Toronto; Department of Medicine, University of Toronto, Toronto, Ontario; and Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University, Montreal, Quebec, Canada. The Canadian Scleroderma Research Group (CSRG) is supported by the Canadian Institutes of Health Research (grant FRN 83518), the Scleroderma Society of Canada and its provincial chapters, Scleroderma Society of Ontario, Sclérodermie Québec, Cure Scleroderma Foundation, Inova Diagnostics Inc. (San Diego, USA), Dr. Fooke Laboratorien GmbH (Neuss, Germany), Euroimmun (Lubeck, Germany), Mikrogen GmbH (Neuried, Germany), Fonds de la recherche en santé du Québec, the Canadian Arthritis Network, and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, Canada. The CSRG has also received educational grants from Pfizer and Actelion. Dr. Hudson is supported by the Fonds de la recherche en Santé du Québec. A.S. Bacher, MD, Department of Internal Medicine, University of Toronto; S. Mittoo, MD, MHS, FRCP, Assistant Professor, Department of Medicine, University of Toronto; M. Hudson, MD, MPH, Assistant Professor, Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University; S. Tatibouet, MSc, Lady Davis Institute, Jewish General Hospital; M. Baron, MD, Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University. Address correspondence to Dr. S. Mittoo, Mount Sinai Hospital L2-003, 60 Murray Street, Toronto, Ontario M5T 3L9, Canada. E-mail: smittoo@mtsinai.on.ca. Accepted for publication March 14, 2013.
Shikha Mittoo
From the Department of Internal Medicine, University of Toronto; Department of Medicine, University of Toronto, Toronto, Ontario; and Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University, Montreal, Quebec, Canada. The Canadian Scleroderma Research Group (CSRG) is supported by the Canadian Institutes of Health Research (grant FRN 83518), the Scleroderma Society of Canada and its provincial chapters, Scleroderma Society of Ontario, Sclérodermie Québec, Cure Scleroderma Foundation, Inova Diagnostics Inc. (San Diego, USA), Dr. Fooke Laboratorien GmbH (Neuss, Germany), Euroimmun (Lubeck, Germany), Mikrogen GmbH (Neuried, Germany), Fonds de la recherche en santé du Québec, the Canadian Arthritis Network, and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, Canada. The CSRG has also received educational grants from Pfizer and Actelion. Dr. Hudson is supported by the Fonds de la recherche en Santé du Québec. A.S. Bacher, MD, Department of Internal Medicine, University of Toronto; S. Mittoo, MD, MHS, FRCP, Assistant Professor, Department of Medicine, University of Toronto; M. Hudson, MD, MPH, Assistant Professor, Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University; S. Tatibouet, MSc, Lady Davis Institute, Jewish General Hospital; M. Baron, MD, Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University. Address correspondence to Dr. S. Mittoo, Mount Sinai Hospital L2-003, 60 Murray Street, Toronto, Ontario M5T 3L9, Canada. E-mail: smittoo@mtsinai.on.ca. Accepted for publication March 14, 2013.
Marie Hudson
From the Department of Internal Medicine, University of Toronto; Department of Medicine, University of Toronto, Toronto, Ontario; and Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University, Montreal, Quebec, Canada. The Canadian Scleroderma Research Group (CSRG) is supported by the Canadian Institutes of Health Research (grant FRN 83518), the Scleroderma Society of Canada and its provincial chapters, Scleroderma Society of Ontario, Sclérodermie Québec, Cure Scleroderma Foundation, Inova Diagnostics Inc. (San Diego, USA), Dr. Fooke Laboratorien GmbH (Neuss, Germany), Euroimmun (Lubeck, Germany), Mikrogen GmbH (Neuried, Germany), Fonds de la recherche en santé du Québec, the Canadian Arthritis Network, and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, Canada. The CSRG has also received educational grants from Pfizer and Actelion. Dr. Hudson is supported by the Fonds de la recherche en Santé du Québec. A.S. Bacher, MD, Department of Internal Medicine, University of Toronto; S. Mittoo, MD, MHS, FRCP, Assistant Professor, Department of Medicine, University of Toronto; M. Hudson, MD, MPH, Assistant Professor, Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University; S. Tatibouet, MSc, Lady Davis Institute, Jewish General Hospital; M. Baron, MD, Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University. Address correspondence to Dr. S. Mittoo, Mount Sinai Hospital L2-003, 60 Murray Street, Toronto, Ontario M5T 3L9, Canada. E-mail: smittoo@mtsinai.on.ca. Accepted for publication March 14, 2013.
Solène Tatibouet
From the Department of Internal Medicine, University of Toronto; Department of Medicine, University of Toronto, Toronto, Ontario; and Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University, Montreal, Quebec, Canada. The Canadian Scleroderma Research Group (CSRG) is supported by the Canadian Institutes of Health Research (grant FRN 83518), the Scleroderma Society of Canada and its provincial chapters, Scleroderma Society of Ontario, Sclérodermie Québec, Cure Scleroderma Foundation, Inova Diagnostics Inc. (San Diego, USA), Dr. Fooke Laboratorien GmbH (Neuss, Germany), Euroimmun (Lubeck, Germany), Mikrogen GmbH (Neuried, Germany), Fonds de la recherche en santé du Québec, the Canadian Arthritis Network, and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, Canada. The CSRG has also received educational grants from Pfizer and Actelion. Dr. Hudson is supported by the Fonds de la recherche en Santé du Québec. A.S. Bacher, MD, Department of Internal Medicine, University of Toronto; S. Mittoo, MD, MHS, FRCP, Assistant Professor, Department of Medicine, University of Toronto; M. Hudson, MD, MPH, Assistant Professor, Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University; S. Tatibouet, MSc, Lady Davis Institute, Jewish General Hospital; M. Baron, MD, Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University. Address correspondence to Dr. S. Mittoo, Mount Sinai Hospital L2-003, 60 Murray Street, Toronto, Ontario M5T 3L9, Canada. E-mail: smittoo@mtsinai.on.ca. Accepted for publication March 14, 2013.
From the Department of Internal Medicine, University of Toronto; Department of Medicine, University of Toronto, Toronto, Ontario; and Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University, Montreal, Quebec, Canada. The Canadian Scleroderma Research Group (CSRG) is supported by the Canadian Institutes of Health Research (grant FRN 83518), the Scleroderma Society of Canada and its provincial chapters, Scleroderma Society of Ontario, Sclérodermie Québec, Cure Scleroderma Foundation, Inova Diagnostics Inc. (San Diego, USA), Dr. Fooke Laboratorien GmbH (Neuss, Germany), Euroimmun (Lubeck, Germany), Mikrogen GmbH (Neuried, Germany), Fonds de la recherche en santé du Québec, the Canadian Arthritis Network, and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, Canada. The CSRG has also received educational grants from Pfizer and Actelion. Dr. Hudson is supported by the Fonds de la recherche en Santé du Québec. A.S. Bacher, MD, Department of Internal Medicine, University of Toronto; S. Mittoo, MD, MHS, FRCP, Assistant Professor, Department of Medicine, University of Toronto; M. Hudson, MD, MPH, Assistant Professor, Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University; S. Tatibouet, MSc, Lady Davis Institute, Jewish General Hospital; M. Baron, MD, Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University. Address correspondence to Dr. S. Mittoo, Mount Sinai Hospital L2-003, 60 Murray Street, Toronto, Ontario M5T 3L9, Canada. E-mail: smittoo@mtsinai.on.ca. Accepted for publication March 14, 2013.
Murray Baron
From the Department of Internal Medicine, University of Toronto; Department of Medicine, University of Toronto, Toronto, Ontario; and Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University, Montreal, Quebec, Canada. The Canadian Scleroderma Research Group (CSRG) is supported by the Canadian Institutes of Health Research (grant FRN 83518), the Scleroderma Society of Canada and its provincial chapters, Scleroderma Society of Ontario, Sclérodermie Québec, Cure Scleroderma Foundation, Inova Diagnostics Inc. (San Diego, USA), Dr. Fooke Laboratorien GmbH (Neuss, Germany), Euroimmun (Lubeck, Germany), Mikrogen GmbH (Neuried, Germany), Fonds de la recherche en santé du Québec, the Canadian Arthritis Network, and the Lady Davis Institute of Medical Research of the Jewish General Hospital, Montreal, Canada. The CSRG has also received educational grants from Pfizer and Actelion. Dr. Hudson is supported by the Fonds de la recherche en Santé du Québec. A.S. Bacher, MD, Department of Internal Medicine, University of Toronto; S. Mittoo, MD, MHS, FRCP, Assistant Professor, Department of Medicine, University of Toronto; M. Hudson, MD, MPH, Assistant Professor, Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University; S. Tatibouet, MSc, Lady Davis Institute, Jewish General Hospital; M. Baron, MD, Division of Rheumatology, Lady Davis Institute, Jewish General Hospital and McGill University. Address correspondence to Dr. S. Mittoo, Mount Sinai Hospital L2-003, 60 Murray Street, Toronto, Ontario M5T 3L9, Canada. E-mail: smittoo@mtsinai.on.ca. Accepted for publication March 14, 2013.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Systemic Sclerosis in Canada's North American Native Population: Assessment of Clinical and Serological Manifestations
Adrienne Bacher, Shikha Mittoo, Marie Hudson, Solène Tatibouet, the Canadian Scleroderma Research Group, Murray Baron
The Journal of Rheumatology May 2013, jrheum.121212; DOI: 10.3899/jrheum.121212
Systemic Sclerosis in Canada's North American Native Population: Assessment of Clinical and Serological Manifestations
Adrienne Bacher, Shikha Mittoo, Marie Hudson, Solène Tatibouet, the Canadian Scleroderma Research Group, Murray Baron
The Journal of Rheumatology May 2013, jrheum.121212; DOI: 10.3899/jrheum.121212